145 related articles for article (PubMed ID: 8514751)
1. The crystallographic structure of the protease from human immunodeficiency virus type 2 with two synthetic peptidic transition state analog inhibitors.
Mulichak AM; Hui JO; Tomasselli AG; Heinrikson RL; Curry KA; Tomich CS; Thaisrivongs S; Sawyer TK; Watenpaugh KD
J Biol Chem; 1993 Jun; 268(18):13103-9. PubMed ID: 8514751
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure of a complex of HIV-1 protease with a dihydroxyethylene-containing inhibitor: comparisons with molecular modeling.
Thanki N; Rao JK; Foundling SI; Howe WJ; Moon JB; Hui JO; Tomasselli AG; Heinrikson RL; Thaisrivongs S; Wlodawer A
Protein Sci; 1992 Aug; 1(8):1061-72. PubMed ID: 1304383
[TBL] [Abstract][Full Text] [Related]
3. Crystal structure of human immunodeficiency virus (HIV) type 2 protease in complex with a reduced amide inhibitor and comparison with HIV-1 protease structures.
Tong L; Pav S; Pargellis C; Dô F; Lamarre D; Anderson PC
Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8387-91. PubMed ID: 8378311
[TBL] [Abstract][Full Text] [Related]
4. The crystal structures at 2.2-A resolution of hydroxyethylene-based inhibitors bound to human immunodeficiency virus type 1 protease show that the inhibitors are present in two distinct orientations.
Murthy KH; Winborne EL; Minnich MD; Culp JS; Debouck C
J Biol Chem; 1992 Nov; 267(32):22770-8. PubMed ID: 1429626
[TBL] [Abstract][Full Text] [Related]
5. HIV protease (HIV PR) inhibitor structure-activity-selectivity, and active site molecular modeling of high affinity Leu [CH(OH)CH2]Val modified viral and nonviral substrate analogs.
Sawyer TK; Staples DJ; Liu L; Tomasselli AG; Hui JO; O'Connell K; Schostarez H; Hester JB; Moon J; Howe WJ
Int J Pept Protein Res; 1992; 40(3-4):274-81. PubMed ID: 1478785
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays.
Dreyer GB; Lambert DM; Meek TD; Carr TJ; Tomaszek TA; Fernandez AV; Bartus H; Cacciavillani E; Hassell AM; Minnich M
Biochemistry; 1992 Jul; 31(29):6646-59. PubMed ID: 1637805
[TBL] [Abstract][Full Text] [Related]
7. Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2.
Tomasselli AG; Hui JO; Sawyer TK; Staples DJ; Bannow C; Reardon IM; Howe WJ; DeCamp DL; Craik CS; Heinrikson RL
J Biol Chem; 1990 Aug; 265(24):14675-83. PubMed ID: 2201691
[TBL] [Abstract][Full Text] [Related]
8. Structure at 2.5-A resolution of chemically synthesized human immunodeficiency virus type 1 protease complexed with a hydroxyethylene-based inhibitor.
Jaskólski M; Tomasselli AG; Sawyer TK; Staples DG; Heinrikson RL; Schneider J; Kent SB; Wlodawer A
Biochemistry; 1991 Feb; 30(6):1600-9. PubMed ID: 1993177
[TBL] [Abstract][Full Text] [Related]
9. A symmetric inhibitor binds HIV-1 protease asymmetrically.
Dreyer GB; Boehm JC; Chenera B; DesJarlais RL; Hassell AM; Meek TD; Tomaszek TA; Lewis M
Biochemistry; 1993 Jan; 32(3):937-47. PubMed ID: 8422397
[TBL] [Abstract][Full Text] [Related]
10. Crystallographic analysis of human immunodeficiency virus 1 protease with an analog of the conserved CA-p2 substrate -- interactions with frequently occurring glutamic acid residue at P2' position of substrates.
Weber IT; Wu J; Adomat J; Harrison RW; Kimmel AR; Wondrak EM; Louis JM
Eur J Biochem; 1997 Oct; 249(2):523-30. PubMed ID: 9370363
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for specificity of retroviral proteases.
Wu J; Adomat JM; Ridky TW; Louis JM; Leis J; Harrison RW; Weber IT
Biochemistry; 1998 Mar; 37(13):4518-26. PubMed ID: 9521772
[TBL] [Abstract][Full Text] [Related]
12. X-ray analyses of aspartic proteinases. III Three-dimensional structure of endothiapepsin complexed with a transition-state isostere inhibitor of renin at 1.6 A resolution.
Veerapandian B; Cooper JB; Sali A; Blundell TL
J Mol Biol; 1990 Dec; 216(4):1017-29. PubMed ID: 2266553
[TBL] [Abstract][Full Text] [Related]
13. X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor.
Swain AL; Miller MM; Green J; Rich DH; Schneider J; Kent SB; Wlodawer A
Proc Natl Acad Sci U S A; 1990 Nov; 87(22):8805-9. PubMed ID: 2247451
[TBL] [Abstract][Full Text] [Related]
14. Role of hydroxyl group and R/S configuration of isostere in binding properties of HIV-1 protease inhibitors.
Petroková H; Dusková J; Dohnálek J; Skálová T; Vondrácková-Buchtelová E; Soucek M; Konvalinka J; Brynda J; Fábry M; Sedlácek J; Hasek J
Eur J Biochem; 2004 Nov; 271(22):4451-61. PubMed ID: 15560786
[TBL] [Abstract][Full Text] [Related]
15. Symmetric fluoro-substituted diol-based HIV protease inhibitors. Ortho-fluorinated and meta-fluorinated P1/P1'-benzyloxy side groups significantly improve the antiviral activity and preserve binding efficacy.
Lindberg J; Pyring D; Löwgren S; Rosenquist A; Zuccarello G; Kvarnström I; Zhang H; Vrang L; Classon B; Hallberg A; Samuelsson B; Unge T
Eur J Biochem; 2004 Nov; 271(22):4594-602. PubMed ID: 15560801
[TBL] [Abstract][Full Text] [Related]
16. Three-dimensional structures of HIV-1 and SIV protease product complexes.
Rose RB; Craik CS; Douglas NL; Stroud RM
Biochemistry; 1996 Oct; 35(39):12933-44. PubMed ID: 8841139
[TBL] [Abstract][Full Text] [Related]
17. Crystallographic analysis of a complex between human immunodeficiency virus type 1 protease and acetyl-pepstatin at 2.0-A resolution.
Fitzgerald PM; McKeever BM; VanMiddlesworth JF; Springer JP; Heimbach JC; Leu CT; Herber WK; Dixon RA; Darke PL
J Biol Chem; 1990 Aug; 265(24):14209-19. PubMed ID: 2201682
[TBL] [Abstract][Full Text] [Related]
18. Kinetic and modeling studies of subsites S4-S3' of Moloney murine leukemia virus protease.
Menéndez-Arias L; Weber IT; Soss J; Harrison RW; Gotte D; Oroszlan S
J Biol Chem; 1994 Jun; 269(24):16795-801. PubMed ID: 8207003
[TBL] [Abstract][Full Text] [Related]
19. A mean field model of ligand-protein interactions: implications for the structural assessment of human immunodeficiency virus type 1 protease complexes and receptor-specific binding.
Verkhivker GM; Rejto PA
Proc Natl Acad Sci U S A; 1996 Jan; 93(1):60-4. PubMed ID: 8552675
[TBL] [Abstract][Full Text] [Related]
20. Three-dimensional structure of a simian immunodeficiency virus protease/inhibitor complex. Implications for the design of human immunodeficiency virus type 1 and 2 protease inhibitors.
Zhao B; Winborne E; Minnich MD; Culp JS; Debouck C; Abdel-Meguid SS
Biochemistry; 1993 Dec; 32(48):13054-60. PubMed ID: 8241159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
